Accelerate Diagnostics, Inc. (AXDX): Price and Financial Metrics
AXDX Price/Volume Stats
Current price | $0.70 | 52-week high | $3.74 |
Prev. close | $0.68 | 52-week low | $0.45 |
Day low | $0.68 | Volume | 148,845 |
Day high | $0.71 | Avg. volume | 274,616 |
50-day MA | $0.71 | Dividend yield | N/A |
200-day MA | $0.99 | Market Cap | 69.90M |
AXDX Stock Price Chart Interactive Chart >
AXDX POWR Grades
- AXDX scores best on the Growth dimension, with a Growth rank ahead of 73.63% of US stocks.
- AXDX's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
- AXDX's current lowest rank is in the Momentum metric (where it is better than 6.83% of US stocks).
AXDX Stock Summary
- ACCELERATE DIAGNOSTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 6.52% of US listed stocks.
- AXDX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 4.94% of US stocks.
- In terms of volatility of its share price, AXDX is more volatile than 92.11% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to ACCELERATE DIAGNOSTICS INC, a group of peers worth examining would be CHRS, GTHX, ASTC, WB, and OCUL.
- AXDX's SEC filings can be seen here. And to visit ACCELERATE DIAGNOSTICS INC's official web site, go to acceleratediagnostics.com.
AXDX Valuation Summary
- AXDX's EV/EBIT ratio is -2; this is 116.67% lower than that of the median Healthcare stock.
- AXDX's price/earnings ratio has moved up 29 over the prior 243 months.
Below are key valuation metrics over time for AXDX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
AXDX | 2023-05-23 | 5.8 | -1.9 | -1.1 | -2 |
AXDX | 2023-05-22 | 5.9 | -1.9 | -1.1 | -2 |
AXDX | 2023-05-19 | 5.9 | -1.9 | -1.1 | -2 |
AXDX | 2023-05-18 | 5.8 | -1.9 | -1.1 | -2 |
AXDX | 2023-05-17 | 6.0 | -1.9 | -1.1 | -2 |
AXDX | 2023-05-16 | 6.1 | -2.0 | -1.2 | -2 |
AXDX Growth Metrics
- The 4 year revenue growth rate now stands at 1513.21%.
- Its year over year revenue growth rate is now at 7.77%.
- Its 4 year cash and equivalents growth rate is now at 298.17%.

The table below shows AXDX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 13.122 | -51.125 | -70.496 |
2022-06-30 | 13.284 | -50 | -63.777 |
2022-03-31 | 12.221 | -46.554 | -67.648 |
2021-12-31 | 11.782 | -47.323 | -77.702 |
2021-09-30 | 11.547 | -45.719 | -73.811 |
2021-06-30 | 12.013 | -45.927 | -83.582 |
AXDX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AXDX has a Quality Grade of D, ranking ahead of 23.75% of graded US stocks.
- AXDX's asset turnover comes in at 0.125 -- ranking 68th of 75 Measuring and Control Equipment stocks.
- AATC, TMO, and BMI are the stocks whose asset turnover ratios are most correlated with AXDX.
The table below shows AXDX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.125 | 0.366 | -0.333 |
2021-03-31 | 0.112 | 0.379 | -0.320 |
2020-12-31 | 0.103 | 0.399 | -0.302 |
2020-09-30 | 0.097 | 0.418 | -0.316 |
2020-06-30 | 0.079 | 0.458 | -0.343 |
2020-03-31 | 0.071 | 0.467 | -0.358 |
AXDX Price Target
For more insight on analysts targets of AXDX, see our AXDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $13.00 | Average Broker Recommendation | 1.7 (Moderate Buy) |
Accelerate Diagnostics, Inc. (AXDX) Company Bio
Accelerate Diagnostics is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company was founded in 1982 and is based in Tucson, Arizona.
Latest AXDX News From Around the Web
Below are the latest news stories about ACCELERATE DIAGNOSTICS INC that investors may wish to consider to help them evaluate AXDX as an investment opportunity.
Q1 2023 Accelerate Diagnostics Inc Earnings CallQ1 2023 Accelerate Diagnostics Inc Earnings Call |
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue EstimatesAccelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 0% and 19.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Accelerate Diagnostics Reports First Quarter 2023 Financial ResultsAccelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023. |
Syneos Health (SYNH) Announces a $7.1 Billion Merger AgreementSyneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium. |
Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe StaysIntensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships. |
AXDX Price Returns
1-mo | -18.34% |
3-mo | 38.89% |
6-mo | -6.67% |
1-year | 15.07% |
3-year | -91.62% |
5-year | -96.57% |
YTD | -0.85% |
2022 | -86.48% |
2021 | -31.13% |
2020 | -55.15% |
2019 | 46.96% |
2018 | -56.11% |
Continue Researching AXDX
Want to see what other sources are saying about Accelerate Diagnostics Inc's financials and stock price? Try the links below:Accelerate Diagnostics Inc (AXDX) Stock Price | Nasdaq
Accelerate Diagnostics Inc (AXDX) Stock Quote, History and News - Yahoo Finance
Accelerate Diagnostics Inc (AXDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...